Kayexalate and Newer Potassium Binders for Hyperkalemia Management

Alternative Therapies and Considerations

• At a potassium level of 5.4 mEq/L, the American Heart Association recommends considering newer potassium binders instead of kayexalate, particularly if the patient is on RAAS inhibitor therapy, as sodium zirconium cyclosilicate (Lokelma) 10 grams three times daily for 48 hours would reduce potassium by approximately 1.1 mEq/L with a faster onset and superior safety profile 1
• The European Society of Cardiology suggests that newer binders enable optimization of cardioprotective RAAS inhibitor therapy rather than requiring dose reduction, with evidence from clinical guidelines supporting the use of these agents 2, 3
• The management of hyperkalemia with binders, such as kayexalate or newer agents, allows for the maintenance of cardioprotective RAAS inhibitor therapy, as recommended by the European Heart Association 2, 4